Business · Companies · 9 hrs ago
Holostem faces collective layoffs for 50 workers after private deal falls through
Holostem faces liquidation and layoffs for 50 workers at its site in Modena, Italy.
The company develops advanced treatments using stem cells, including therapies for rare diseases such as epidermolysis bullosa.
It began as a university spin-off and developed Holoclar, the first stem-cell-based medicine approved by the European Medicines Agency.
A Dutch company showed interest in buying Holostem, but its public owner, the ENEA Tech and Biomedical Foundation, rejected the offer, saying it lacked sufficient guarantees.
The foundation acquired the business in 2023 to preserve its scientific and production assets, but the company has since faced financial uncertainty.
Workers say they have received no clear explanation about the rejected offer and remain at the company while awaiting confirmation that layoffs will proceed.
The Emilia-Romagna regional government has questioned whether all possible steps were taken to protect the company and its skilled workforce.
Workers plan to join a general strike on 20 November as they await further clarification.
Holostem has announced a collective layoff procedure affecting 50 employees after a potential private deal fell through.
The company develops stem-cell-based advanced therapies, including treatments for rare diseases such as epidermolysis bullosa.
Its sole owner, the ENEA Tech and Biomedical Foundation, rejected an offer from a Dutch partner, saying it lacked sufficient guarantees.
Workers say they have not been told how the offer was handled and remain at the company, hoping to resume treatments for patients.
The Emilia-Romagna region expressed regret and questioned whether the ministry and owner had done all they could to protect the company.
- Who
- Holostem and its 50 employees are affected. The company is owned by the ENEA Tech and Biomedical Foundation.
- What
- A collective layoff procedure has been announced after a potential private deal fell through.
- When
- The announcement was reported on November 13, 2026. Workers said the offer reached the owner on October 15.
- Where
- Modena, in Italy’s Emilia-Romagna region.
- Why
- The Foundation rejected a potential Dutch partner’s offer, saying it did not provide sufficient guarantees, while the company’s liquidation procedure continued.
Holostem employees
ENEA Tech and Biomedical Foundation
Offer and layoffs
Holostem employees
Workers say they received no explanation about the potential buyer’s exit and argue that laying off 50 people cannot protect Holostem’s expertise.
ENEA Tech and Biomedical Foundation
The Foundation rejected the Dutch partner’s offer because it did not present sufficient guarantees.
Protecting the company
Holostem employees
Employees say they remain at work, believe in the project and are ready to resume therapies for patients.
ENEA Tech and Biomedical Foundation
The Foundation’s stated reason for rejecting the offer was that it lacked sufficient guarantees.
Holostem began as a university spin-off of the University of Modena and Reggio Emilia.
Holostem developed Holoclar, described as the first stem-cell-based medicine approved by the European Medicines Agency.
The ENEA Tech and Biomedical Foundation acquired the company’s business unit.
A potential private partner’s offer reached Holostem’s owner, according to a workers’ representative.
Corriere della Sera reported the collective layoff procedure for 50 employees.
Holostem employees said they would join a general strike called by the CGIL.
- Employees affected
- 50
- Potential partner
- A company from the Netherlands specializing in the sale of stem-cell-based medicines
- Owner
- ENEA Tech and Biomedical Foundation
- Company founded
- 2008
- Holoclar developed
- 2015
- Planned strike
- November 20, 2026
What people are saying
We are stuck at October 15, when the offer reached our owner, and we do not know whether or how it was handled.
Laying off 50 people cannot be a path to protection.
We must ask whether the Ministry of Enterprises and Made in Italy and the owner really did everything possible to safeguard a national asset of research and innovation capacity, which cannot exist without the professionals who made it possible.